MDR-1 expression and response to vincristine, doxorubicin, and dexamethasone chemotherapy in multiple myeloma refractory to alkylating agents.

Cornelissen, J J; Sonneveld, P; Schoester, M; Raaijmakers, H G; Nieuwenhuis, H K; Dekker, A W; Lokhorst, H M

Cornelissen, J J; Sonneveld, P; Schoester, M; Raaijmakers, H G; Nieuwenhuis, H K; Dekker, A W; Lokhorst, H M.

Affiliation

Cornelissen JJ; Department of Haematology, University Hospital Utrecht, The Netherlands.

J Clin Oncol ; 12(1): 115-9, 1994 Jan.

Article in En | MEDLINE | ID: mdl-7903690

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Carrier Proteins/analysis; Membrane Glycoproteins/analysis; Multiple Myeloma/drug therapy; Multiple Myeloma/metabolism; Neoplasm Proteins/analysis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Adult; Aged; Alkylating Agents/therapeutic use; Dexamethasone/administration & dosage; Doxorubicin/administration & dosage; Drug Resistance; Female; Gene Expression; Humans; Male; Middle Aged; Predictive Value of Tests; Prognosis; Survival Analysis; Vincristine/administration & dosage

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Membrane Glycoproteins / Antineoplastic Combined Chemotherapy Protocols / Carrier Proteins / Multiple Myeloma / Neoplasm Proteins Type of study: Prognostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: J Clin Oncol Year: 1994 Document type: Article Affiliation country: Netherlands Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links